Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg); levodopa, quantity: 200 mg - tablet, uncoated - excipient ingredients: iron oxide red; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; mannitol; pregelatinised maize starch; docusate sodium; ethylcellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: roche (philippines), inc.; distributor: roche (philippines), inc. - levodopa , benserazide (as hydrochloride) - tablet - 200 mg/ 50 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 50mg ; 200mg

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - capsule, hard - 200 mg/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, dispersible - excipient ingredients: citric acid; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg;   - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg   excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

Malta - English - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 50 mg levodopa 200 mg - anti-parkinson drugs

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, dispersible - excipient ingredients: magnesium stearate; pregelatinised maize starch; citric acid; microcrystalline cellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - benserazide hcl 57mg equivalent to benserazide; levodopa - tablet - 50 mg - benserazide hcl 57mg equivalent to benserazide 50 mg; levodopa 200 mg